Compare · DXCM vs MDAI
DXCM vs MDAI
Side-by-side comparison of DexCom Inc. (DXCM) and Spectral AI Inc. (MDAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MDAI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $26.59B, about 488.7x MDAI ($54.4M).
- Over the past year, DXCM is down 21.3% and MDAI is down 18.8% - MDAI leads by 2.5 points.
- DXCM has been more active in the news (18 items in the past 4 weeks vs 5 for MDAI).
- DXCM has more recent analyst coverage (25 ratings vs 1 for MDAI).
- Company
- DexCom Inc.
- Spectral AI Inc.
- Price
- $68.89-0.24%
- $1.73-1.71%
- Market cap
- $26.59B
- $54.4M
- 1M return
- -4.14%
- -34.66%
- 1Y return
- -21.33%
- -18.82%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 18
- 5
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
Latest MDAI
- Spectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
- Spectral AI to Participate in 2026 British Burn Association Annual Conference
- Spectral AI Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Director Dimaio John Michael was granted 17,500 shares, increasing direct ownership by 0.66% to 2,687,847 units (SEC Form 4)
- Spectral AI Announces Voting Results of Annual Meeting of Stockholders
- Director Dimaio John Michael was granted 32,233 shares, increasing direct ownership by 1% to 2,670,347 units (SEC Form 4)
- Spectral AI Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
- Director Sadagopan Deepak was granted 25,000 shares (SEC Form 4)
- Director Cotton Richard John was granted 14,700 shares, increasing direct ownership by 15% to 111,477 units (SEC Form 4)